INVENTIVA (EPA:IVA) Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Transparency directive : regulatory news
21/10/2024 14:30
source : webdisclosure.com